Canada's MindWalk Q4 revenue misses estimates

Overview

• Canada Bio-Native AI infrastructure firm's Q4 revenue missed analyst expectations

• Fiscal 2026 revenue rose 46% yr/yr as company completed pivot to BioIntelligence infrastructure

• Company authorized share repurchase program for up to 2.3 mln shares, about 5% of shares outstanding

Outlook

• Company did not provide specific guidance for the current quarter or full year

Result Drivers

• BIOINTELLIGENCE FOCUS - Co said revenue growth was driven by completion of its pivot to BioIntelligence infrastructure and deployment of HYFT Technology

• RECURRING PLATFORM REVENUE - Co signed its first two contracted, recurring enterprise LensAI agreements, contributing to revenue growth

• OPERATING EXPENSE DECLINE - Lower operating expenses reflected non-recurrence of prior-year non-cash amortization and impairment charges

Company press release: ID:nBw8Yv1jPa

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for MindWalk Holdings Corp is $5.00, about 242.5% above its July 21 closing price of $1.46

Reuters Recommended Reads

• July 21 - Pegasystems Q2 adjusted EPS misses as AI shifts delay purchases

• July 21 - France's Sidetrade H1 revenue rises 19% on AI product growth

• July 22 - IBM cuts yearly revenue growth forecast as customers prioritize AI infrastructure spending

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)